Literature DB >> 19808327

Pheochromocytoma-induced cardiomyopathy is modulated by the synergistic effects of cell-secreted factors.

Hector R Mobine1, Aaron B Baker, Libin Wang, Hiroko Wakimoto, Kurt C Jacobsen, Christine E Seidman, J G Seidman, Elazer R Edelman.   

Abstract

BACKGROUND: Pheochromocytomas are rare tumors derived from the chromaffin cells of the adrenal medulla. Although these tumors have long been postulated to induce hypertension and cardiomyopathy through the hypersecretion of catecholamines, catecholamines alone may not fully explain the profound myocardial remodeling induced by these tumors. We sought to determine whether changes in myocardial function in pheochromocytoma-induced cardiomyopathy result solely from catecholamines secretion or from multiple pheochromocytoma-derived factors. METHODS AND
RESULTS: Isolated cardiomyocytes incubated with pheochromocytoma-conditioned growth media contracted at a higher frequency than cardiomyocytes incubated with norepinephrine (NE) only. Sprague-Dawley rats and black-6 mice were implanted with agarose-encapsulated pheochromocytoma (PC12) cells, dihydroxyphenylalanine decarboxylase knock-out PC12 cells deficient in NE (PC12-KO), or NE-secreting pumps. PC12 cell implantation increased left ventricular dilation by 35+/-6% and 9.6+/-1.4% and reduced left ventricular fractional shortening by 20+/-3% and 28+/-4% in rats and mice compared with animals dosed only with NE, respectively. Elimination of NE secretion in PC12-KO cells induced neither cardiac dilation (3.9%+/-1.8% increase versus control) nor changes in (1.9%+/-0.4% reduction) fractional shortening compared to controls.
CONCLUSIONS: Pheochromocytomas induce a greater degree of cardiomyopathy than equivalent doses of NE, suggesting pheochromocytoma-induced cardiomyopathy is not solely mediated by NE, rather pheochromocytoma secretory factors in combination with catecholamines act synergistically to induce greater cardiac damage than catecholamines alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808327      PMCID: PMC2769512          DOI: 10.1161/CIRCHEARTFAILURE.108.813261

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  44 in total

1.  Pheochromocytoma.

Authors:  S Warren; R N Chute
Journal:  Cancer       Date:  1972-02       Impact factor: 6.860

2.  Isoproterenol-induced cardiac necrosis.

Authors:  D S Kahn; G Rona; C I Chappel
Journal:  Ann N Y Acad Sci       Date:  1969-01-31       Impact factor: 5.691

3.  Effect of adrenergic alpha- and beta-receptor blocking drugs on the myocardial lesions induced by sympathomimetic amines.

Authors:  G Méhes; G Papp; K Rajkovits
Journal:  Acta Physiol Acad Sci Hung       Date:  1967

4.  Desensitization of beta-adrenergic receptors by pheochromocytoma.

Authors:  G Tsujimoto; W M Manger; B B Hoffman
Journal:  Endocrinology       Date:  1984-04       Impact factor: 4.736

Review 5.  [Clinical use of markers of neurohormonal activation in heart failure].

Authors:  Eulalia Roig Minguell
Journal:  Rev Esp Cardiol       Date:  2004-04       Impact factor: 4.753

6.  Adrenergic receptors in human and experimental pheochromocytoma.

Authors:  M D Snavely; H J Motulsky; D T O'Connor; M G Ziegler; P A Insel
Journal:  Clin Exp Hypertens A       Date:  1982

7.  Contribution of alpha-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy.

Authors:  S E Downing; J C Lee
Journal:  Circ Res       Date:  1983-04       Impact factor: 17.367

8.  Pheochromocytoma: state-of-the-art and future prospects.

Authors:  Emmanuel L Bravo; Rodrigo Tagle
Journal:  Endocr Rev       Date:  2003-08       Impact factor: 19.871

9.  Epinephrine induced myocardial necrosis: effects of aminophylline and adrenergic blockade.

Authors:  R G Blaiklock; E M Hirsh; S Dapson; B Paino; D Lehr
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-11

10.  Coronary vasoconstriction and catecholamine cardiomyopathy.

Authors:  M Simons; S E Downing
Journal:  Am Heart J       Date:  1985-02       Impact factor: 4.749

View more
  7 in total

1.  A case of pheochromocytoma presenting with cardiopulmonary arrest.

Authors:  Takashi Touma; Takafumi Miyara; Yoji Taba
Journal:  J Cardiol Cases       Date:  2019-08-29

2.  Pheochromocytoma presenting as acute decompensated heart failure reversed with medical therapy.

Authors:  Christopher M Mulla; Paul Ellis Marik
Journal:  BMJ Case Rep       Date:  2012-07-19

3.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 4.  A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches.

Authors:  Vivek Sarohi; Shriya Srivastava; Trayambak Basak
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-01

5.  Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow.

Authors:  Peter L Voyvodic; Daniel Min; Robert Liu; Evan Williams; Vipul Chitalia; Andrew K Dunn; Aaron B Baker
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

Review 6.  Pheochromocytoma resection: Current concepts in anesthetic management.

Authors:  Harish Ramakrishna
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Jul-Sep

Review 7.  Subclinical cardiac damage in cancer patients before chemotherapy.

Authors:  Iacopo Fabiani; Giorgia Panichella; Alberto Aimo; Chrysanthos Grigoratos; Giuseppe Vergaro; Nicola Riccardo Pugliese; Stefano Taddei; Daniela Maria Cardinale; Claudio Passino; Michele Emdin; Alberto Giannoni
Journal:  Heart Fail Rev       Date:  2021-07-27       Impact factor: 4.654

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.